Infectious Diseases (all articles) | Page 79 of 298 | Links Medicus Content Curation & Alerts in Medicine

Short Review: Metronidazole-induced neurotoxicity.

2 Nov, 2021 | 02:41h | UTC

Metronidazole-induced neurotoxicity – Canadian medical Association Journal

Commentary on Twitter

The ability of metronidazole to cause neurotoxicity is not widely appreciated. Here's our quick overview led by @DanicaQuickfall, just out in @CMAJ.
https://t.co/7sggYzCzGN pic.twitter.com/miW0trFuYv

— David Juurlink (@DavidJuurlink) October 25, 2021

Observational study suggests a third dose of the Pfizer COVID-19 vaccine can prevent severe COVID-19-related outcomes, compared with only two doses received at least 5 months before.

31 Oct, 2021 | 20:14h | UTC

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study – The Lancet

Invited Commentary: Boosters appear effective, but are they always needed? – The Lancet

Commentaries on Twitter

Nice analysis of boosters in @TheLancet Fri.: https://t.co/KqXInFa3a9

But I want to highlight one number:

Risk of severe disease w no booster & no coexisting conditions = 1 in 32,000 (3 per 100k).

If you have no other medical problems, this is not an urgent priority. pic.twitter.com/Qwcwsf6LIY

— David Dowdy (@davidwdowdy) October 31, 2021

Study in Israel suggests third dose of BNT162b2 mRNA vaccine effective in protecting individuals against severe COVID-19-related outcomes, compared with receiving only two doses at least 5 months before. https://t.co/g3vFqVFZLI pic.twitter.com/HfbBAPY8qP

— The Lancet (@TheLancet) October 31, 2021

Adding to the body of data for booster shot effectiveness, a new @TheLancet report of over 728,000 people w/ 3 shots vs >728,000 matched controls (2 shots):
93% reduction of Covid hospitalizationshttps://t.co/cVpANpnkHs pic.twitter.com/LlBwWi2Vtw

— Eric Topol (@EricTopol) October 30, 2021

Study shows fully vaccinated individuals can still catch SARS-CoV-2 delta variant and efficiently transmit infection in household settings, including to fully vaccinated contacts.

31 Oct, 2021 | 20:16h | UTC

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study – The Lancet Infectious Diseases

Commentaries:

COVID vaccines effective but household transmission of delta a risk for 1 in 4 – Imperial College London

What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant? – The Lancet Infectious Diseases

CoVID-19 vaccines lower risk of infection with delta variant, but infection can still be passed on in household settings – the Lancet

COVID vaccines protect against Delta but don’t fully stop disease spread – CIDRAP

Covid: Double vaccinated can still spread virus at home – BBC

Commentary on Twitter

NEW—#COVID19 vaccines lower the risk of infection with the #DeltaVariant. However, infection can still be passed on in household settings after two doses.

Authors urge unvaccinated to get vaccinated & those eligible to receive a booster. 1/2 https://t.co/jq8DCK69Ww pic.twitter.com/1XzHnKCF01

— The Lancet (@TheLancet) October 28, 2021

Editorial: Safety and efficacy of antivirals against SARS-CoV-2 – “we need evidence not optimism”.

31 Oct, 2021 | 20:11h | UTC

Safety and efficacy of antivirals against SARS-CoV-2 – The BMJ

Commentary on Twitter

"Effective antivirals have an obvious appeal, but this must not cloud objective and transparent decision making." @dpsg108 and colleagues on the government's stockpiling of molnupiravir and PF-07321332+ritonavir for covid-19https://t.co/JUj1Y9op3P

— The BMJ (@bmj_latest) October 28, 2021

CDC Study: COVID-19 vaccine associated with 5 times the protection of ‘natural immunity’.

31 Oct, 2021 | 20:09h | UTC

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries:

COVID-19 vaccine gives 5 times the protection of ‘natural immunity,’ data show – CIDRAP

COVID shots more protective than past infection, study shows – Associated Press

Commentary on Twitter

⚠️BREAKING—REINFECTION & NATURAL IMMUNITY—new CDC study in hospitalized adults finds: unvaccinated people with prior #COVID19 infection recently were **5 times more likely** to be reinfected / get breakthrough versus people recently fully vaccinated! 🧵 https://t.co/VGmWPmm5lE pic.twitter.com/mlt5fJ3643

— Eric Feigl-Ding (@DrEricDing) October 29, 2021

Cohort Study: Among patients with ST-segment elevation myocardial infarction, a concomitant Covid-19 diagnosis is associated with increased in-hospital mortality.

31 Oct, 2021 | 20:10h | UTC

Association Between COVID-19 Diagnosis and In-Hospital Mortality in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction – JAMA

Editorial: Myocardial Infarction During the COVID-19 Pandemic – JAMA

Commentary: STEMI and COVID-19 Often a Lethal Combo, Affirms Largest Study Yet – TCTMD

Commentary from the author on Twitter (thread – click for more)

1/8 It was not unexpected that pts w/ #STEMI would fare worse w/ than w/o #COVID19 https://t.co/B7oWnJunEa

— herbaronowMD (@herbaronowMD) October 29, 2021

Opinion | Is Moderna really better than Pfizer—or is it just a higher dose?

31 Oct, 2021 | 20:06h | UTC

Is Moderna Really Better Than Pfizer—Or Is It Just a Higher Dose? – The Atlantic

Commentary on Twitter

Nice piece @theatlantic explores question of: Does Moderna give better protection than Pfizer, which gives better protection than J&J (the data would say yes to both)? And – if so – is it simply a matter of the relative doses? https://t.co/Bqav2pNNi7

— Bob Wachter (@Bob_Wachter) October 30, 2021

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

29 Oct, 2021 | 10:20h | UTC

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’ – Cleveland Clinic Journal of Medicine

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

Review: How I manage a patient with MRSA bacteremia.

31 Oct, 2021 | 19:54h | UTC

How I manage a patient with MRSA bacteraemia – Clinical Microbiology and Infection

The effectiveness of the AstraZeneca vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo was 77.9% against symptomatic Covid-19, 87.6% against hospitalization, and 93.6% against death.

29 Oct, 2021 | 10:25h | UTC

Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo – Nature Medicine

Commentary on Twitter (thread – click for more)

https://twitter.com/MHitchingsEpi/status/1453779176826105857

Under-reporting of deaths limits our understanding of true burden of covid-19.

29 Oct, 2021 | 10:18h | UTC

Under-reporting of deaths limits our understanding of true burden of covid-19 – The BMJ

Study shows COVID-19 has caused the biggest decrease in life expectancy since World War II.

Just how do deaths due to COVID-19 stack up?

Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset.

Exploring the gap between excess mortality and COVID-19 deaths in 67 countries.

Report: Three new estimates of India’s all-cause excess mortality during the COVID-19 Pandemic – pandemic death toll estimated to be between 3.4 million and 4.9 million excess deaths.

COVID-19 has caused 6.9 million deaths globally, more than double what official reports show

Commentary on Twitter

Mortality data have been essential in understanding the spread of covid-19 and navigating the trade-offs that underlie political decision making, yet under-reporting in official death records has greatly obscured this understanding.

What should be done?https://t.co/pI8aVpa3NR

— The BMJ (@bmj_latest) October 14, 2021

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.

29 Oct, 2021 | 10:16h | UTC

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern – Science

Commentary from the author on Twitter (thread – click for more)

Antibodies come and go, but memory cells are forever (maybe not forever, but at least 6 months). Our latest in @ScienceMagazine: https://t.co/YHHBMrMsTA

How long does immune memory last after #mRNA vax? Is it effective vs. variants? What about “boosted” responses?

Full 🧵⬇️… pic.twitter.com/oZ5BxLuVdw

— Rishi Goel (@rishirajgoel) October 14, 2021

Nine Pandemic Words That Almost No One Gets Right.

29 Oct, 2021 | 10:12h | UTC

Nine Pandemic Words That Almost No One Gets Right – The Atlantic

RCT: Early treatment of Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab is associated with reduced risk of hospitalization.

28 Oct, 2021 | 10:20h | UTC

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab – New England Journal of Medicine

Commentary on Twitter

In this phase 3 trial, sotrovimab or placebo was administered to outpatients within 5 days after the onset of #COVID19 symptoms. Patients receiving sotrovimab had a lower incidence of hospitalization for any reason. #IDTwitter https://t.co/4VcgoK3xac pic.twitter.com/W82v3jNRmB

— NEJM (@NEJM) October 27, 2021

Merck to allow other nations to produce new COVID-19 antiviral.

28 Oct, 2021 | 10:18h | UTC

Merck to allow other nations to produce new COVID-19 antiviral – CIDRAP

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

28 Oct, 2021 | 10:22h | UTC

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial – The Lancet Global Health

Commentaries:

Expert reaction to study looking at fluvoxamine as a COVID-19 treatment in high-risk outpatients with early-diagnosed COVID-19 – Science Media Centre

The TOGETHER Trial: COVID-19 and Fluvoxamine Take Two – REBEL EM

The antidepressant fluvoxamine can keep COVID-19 patients out of the hospital – ScienceNews

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Commentary on Twitter

NEW in @LancetGH: Using SSRI #fluvoxamine to treat high-risk outpatients with early-diagnosed #COVID19 reduced the need for prolonged observation in an emergency setting or hospitalisation: largest trial to date. https://t.co/BVtMju74lp @TogetherTrial pic.twitter.com/F1FnZuyqdY

— The Lancet (@TheLancet) October 27, 2021

Two observational studies cast doubt on the effects of school closures to reduce the spread of Covid-19.

28 Oct, 2021 | 10:17h | UTC

Study 1: No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020 – Nature Medicine

Study 2: The impact of school opening model on SARS-CoV-2 community incidence and mortality – Nature Medicine

Commentaries on Twitter

Results from a study in the US published in @NatureMedicine indicate that schools can reopen for in-person learning without substantially increasing community case rates of SARS-CoV-2. However, the impacts are variable and more study is needed. https://t.co/NFt1vNNb76 pic.twitter.com/fNgsJn6WLg

— Nature Portfolio (@NaturePortfolio) October 27, 2021

(thread – click for more)

2 new @NatureMedicine papers
First from half of US public school data
"Schools can open for in-person learning during the pandemic with minimal contribution to sustained community incidence of infections, provided other public safety measures are adopted."https://t.co/gn8MzrYVxE pic.twitter.com/qGfQLMzDEW

— Eric Topol (@EricTopol) October 27, 2021